M&A Deal Summary

Curia Acquires Aptuit - Aseptic Clinical Manufacturing

On January 9, 2015, Curia, Inc. acquired life science company Aptuit - Aseptic Clinical Manufacturing from Aptuit LLC for 60M USD

Acquisition Highlights
  • This is Curia’s 3rd transaction in the Life Science sector.
  • This is Curia’s 4th largest (disclosed) transaction.
  • This is Curia’s 2nd transaction in the United Kingdom.

M&A Deal Summary

Date 2015-01-09
Target Aptuit - Aseptic Clinical Manufacturing
Sector Life Science
Buyer(s) Curia, Inc.
Sellers(s) Aptuit LLC
Deal Type Divestiture
Deal Value 60M USD

Target

Aptuit - Aseptic Clinical Manufacturing

Glasgow, United Kingdom

Search 170,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Curia, Inc.

Albany, New York, United States

website


Category Company
Founded 1991
SectorLife Science
Employees2,220
Revenue 402M USD (2015)
DESCRIPTION

Curia is a provider of global contract research and manufacturing services to the pharmaceutical and biotechnology industries. The Company's services include Drug Discovery, such as medicinal chemistry, discovery biology, and in vitro ADME; Development, such as pre-formulation, formulation and validation; and Manufacturing, such as cGMP API manufacturing. Curia was founded in 1991 and is based in Albany, New York.


DEAL STATS #
Overall 5 of 10
Sector (Life Science) 3 of 8
Type (Divestiture) 1 of 2
Country (United Kingdom) 2 of 2
Year (2015) 1 of 3
Size (of disclosed) 4 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-06-02 OSO BioPharmaceuticals Manufacturing LLC

Albuquerque, New Mexico, United States

OsoBio is a leading contract manufacturer of injectable pharmaceutical products. The company provides glass vial filling and lyophilization services for drugs and biologics that are either approved for commercial marketing or in clinical development. With facilities equipped to handle highly potent and toxic active pharmaceutical ingredients, OsoBio focuses on the production of products that require special or complex handling.

Buy $110M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-16 Gadea Grupo Farmacéutico SL (Gadea Pharmaceutical Group)

Valladolid, Spain

Gadea Grupo Farmacéutico SL (Gadea Pharmaceutical Group) is a technically complex active pharmaceutical ingredients (APIs) and finished drug product.

Buy $174M

Seller(S) 1

SELLER

Aptuit LLC

Greenwich, Connecticut, United States

website


Category Company
Founded 2004
SectorLife Science
Revenue 88M USD (2016)
DESCRIPTION

Aptuit LLC is a provider of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and Switzerland.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United Kingdom) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-06-30 GlaxoSmithKline - Medicines Research Centre

Verona, Italy

GlaxoSmithKline - Medicines Research Center is a global network of operations that provides a full suite of development services. The agreement also enhances Aptuit’s ability to serve customers working to develop compounds for high-value and strategically important therapeutic areas such as neurosciences discovery and development, as well as cardiovascular and infectious diseases.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-04-21 Exquiron Biotech AG

Reinach, Switzerland

Exquiron Biotech AG is a specialist Contract Research Organization dedicated to early phase drug discovery solutions. Exquiron offers industry major expertise in assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas.

Buy -